Mithramycin targets head and neck cancer stem cells by inhibiting Sp1 and UFMylation.

ABSTRACT:

Background

The development of resistance to therapy is characteristic of head and neck squamous cell carcinoma (HNSCC), the 6th most common cancer, and is often attributed to cancer stem cells (CSCs). By proteomic approach, we determined that UFMylation plays an important role in HNSCC CSCs. Because of the necessity for innovative therapeutic strategies, we explore here the therapy targeting CSCs based on mithramycin and its inhibitory effect on Sp1 transcription factor, UFMylation, and CSCs survival and stemness.

Methods

HNSCC-derived cancer cell lines Detroit 562, FaDu, and Cal27, and tumor spheres are used as a model for CSCs. Proteomic analysis identified the importance of the UFMylation pathway in CSCs which we further studied by bioinformatics, western blot, immunocyto

SUBMITTER: Derfi KV 

PROVIDER: S-EPMC11660673 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature